Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27315111 | 0.82 | GAA (0.53) | NPC1RAB9AALDH1A1MAPTRXFP1 | |
| SCHEMBL13938473 | 0.78 | NPC1 (0.46) | NPC1RAB9AALDH1A1MAPTRXFP1 | |
| SCHEMBL337724 | 0.75 | NPC1 (0.44) | NPC1RAB9AALDH1A1MAPTRXFP1 | |
| SCHEMBL5201218 | 0.74 | SMYD3 (0.44) | NPC1RAB9AALDH1A1MAPTRXFP1 | |
| SCHEMBL31458552 | 0.72 | — | — | |
| SCHEMBL10045647 | 0.71 | LMNA (0.44) | NPC1RAB9AALDH1A1MAPTRXFP1 | |
| SCHEMBL10762089 | 0.70 | RAB9A (0.38) | NPC1RAB9AALDH1A1MAPTGAA | |
| SCHEMBL8710562 | 0.69 | NPSR1 (0.35) | ALDH1A1L3MBTL1 | |
| SCHEMBL21340604 | 0.69 | ALDH1A1 (0.57) | NPC1RAB9AALDH1A1MAPTRXFP1 | |
| SCHEMBL13779949 | 0.67 | ALDH1A1 (0.59) | NPC1RAB9AALDH1A1MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11800869-B2 | Use of 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid, 1-methyl 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid and 1-alkyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid for improving growth performance in plants | Advanced Crop Chem LLP (US) | 2023-10-31 | — | — | US | disclosed |
| US-20220174953-A1 | USE OF 6-OXO-1,4,5,6-TETRAHYDROPYRIDIZIN-3-CARBOXYLIC ACID, 1-METHYL 6-OXO-1,4,5,6-TETRAHYDROPYRIDIZIN-3-CARBOXYLIC ACID AND 1-AKLYL-6-OXO-1,4,5,6-TETRAHYDROPYRIDAZINE-3-CARBOXYLIC ACID FOR IMPROVING GROWTH PERFORMANCE IN PLANTS | Advanced Crop Chem LLP (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220174953-A1 | USE OF 6-OXO-1,4,5,6-TETRAHYDROPYRIDIZIN-3-CARBOXYLIC ACID, 1-METHYL 6-OXO-1,4,5,6-TETRAHYDROPYRIDIZIN-3-CARBOXYLIC ACID AND 1-AKLYL-6-OXO-1,4,5,6-TETRAHYDROPYRIDAZINE-3-CARBOXYLIC ACID FOR IMPROVING GROWTH PERFORMANCE IN PLANTS | Advanced Crop Chem LLP (US) | 2022-06-09 | — | — | US | disclosed |
| US-8987312-B2 | Alpha-keto heterocycles as FAAH inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987312-B2 | Alpha-keto heterocycles as FAAH inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987312-B2 | Alpha-keto heterocycles as FAAH inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2011055270-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2010005572-A2 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010005572-A2 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-14 | — | — | WO | disclosed |
| US-5883090-A | Endothelin receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | FAAH, FAAH2, FADS1 | NPC1 1567/4885RAB9A 2964/4885ALDH1A1 170/4885 |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | HRH2, CRHR2, CRHR1 | NPC1 1905/4885RAB9A 2524/4885ALDH1A1 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.